Solan Headlines

Myocardial Infarction Pipeline, NDA Approvals, Clinical Trials, Product Developmental Activities | Major Companies – Tasly Pharmaceuticals, Rion, Olatec Therapeutics, and Others

 Breaking News
  • No posts were found

Myocardial Infarction Pipeline, NDA Approvals, Clinical Trials, Product Developmental Activities | Major Companies – Tasly Pharmaceuticals, Rion, Olatec Therapeutics, and Others

April 26
23:10 2023
Myocardial Infarction Pipeline, NDA Approvals, Clinical Trials, Product Developmental Activities | Major Companies - Tasly Pharmaceuticals, Rion, Olatec Therapeutics, and Others

DelveInsight’s, “Myocardial Infarction Pipeline Insight 2023” report provides comprehensive insights about 60+ companies and 62+ pipeline drugs in Myocardial Infarction pipeline landscape. It covers the Myocardial Infarction pipeline drug profiles, including Myocardial Infarction clinical trials and nonclinical stage products. It also covers the Myocardial Infarction therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.


Key Takeaways from the Myocardial Infarction Pipeline Report


  • DelveInsight’s Myocardial Infarction pipeline report depicts a robust space with 60+ active players working to develop 62+ pipeline therapies for Myocardial Infarction treatment.


  • The leading Myocardial Infarction Companies includes Zensun (Shanghai) Sci & Tech, Valo Health, Inc., Translational Sciences, Tenaya Pharma, Tasly Pharmaceuticals, SmartPharma, Shanghai Life Science & Technology, Serpin Pharma, Serca Pharmaceutical, Rubicon Biotechnology, R-Pharm, Rion, ResoTher Pharma, RegeneRx, Regencor, Recardio, Inc., Qurgen Inc., Philip Morris International Inc., Olatec Therapeutics, NuvOx Pharma, NEXEL Co., Ltd., MimeTech Srl, Mesoblast, Inc., Mesoblast, Matricelf, MandalMed, LTT Bio-Pharma, Kancera, Jemincare, Inoterm, Innolife, Dexa Medica, DeckTherapeutics, Cynata Therapeutics, Bayer, AstraZeneca, Arthersys, Inc, aptaTargets, APT Therapeutics, Aposcience, Acticor Biotech, Abcentra, and others


  • Promising Myocardial Infarction Pipeline Therapies includes FARXIGA/FORXIGA (dapagliflozin), JARDIANCE (empagliflozin), Olpasiran (AMG860), Pelacarsen (TQJ230), Selatogrel, FDY-5301, CSL112, IMT-358, CL2020, MEDI6570, KAND567, Asundexian, Dutogliptin, MPC-25-IC, and others.


  • The Myocardial Infarction companies and academics are working to assess challenges and seek opportunities that could influence Myocardial Infarction R&D. The Myocardial Infarction pipeline therapies under development are focused on novel approaches to treat/improve Myocardial Infarction. 


To explore more information on the latest breakthroughs in the Myocardial Infarction Pipeline treatment landscape of the report, click here @ Myocardial Infarction Pipeline Outlook


Myocardial Infarction Overview

Myocardial Infarction in which the word infarction means necrosis or death of tissue is commonly known as “Heart attack” and it occurs due to reduced or complete cessation of blood flow to a portion of myocardium resulting in its necrosis due to lack of adequate oxygen supply. The accumulation of plaques, white blood cells, cholesterol, and fat in coronary arteries causes its narrowing and blockage leading to formation of blood clots which in turn restricts the flow of blood to the heart.


Recent Developmental Activities in the Myocardial Infarction Treatment Landscape


  • In November 2022, Amgen presented end-of-treatment data from its Phase II OCEAN (a)-DOSE study of olpasiran during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions and simultaneously published in the New England Journal of Medicine.


  • As per the Q32022 investor presentation of AstraZeneca data, readouts from the Phase III (DAPA-MI) trial of FARXIGA/FORXIGA is anticipated by 2H 2023. With an estimated key regulatory submission acceptance after 2023


  • In June 2021, Idorsia announced the initiation of the Phase III registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered SC selatogrel in suspected AMI


  • In September 2020, the FDA granted Fast Track designation for the development of JARDIANCE to prevent hospitalization for heart failure and reduce the risk of mortality in patients with and without diabetes who have had an acute MI


  • In July 2020, AstraZeneca was granted Fast Track designation in the US for the development of FARXIGA to reduce the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults following an AMI or heart attack.


  • In May 2022, the company presented the Phase II safety results of the drug at the World Congress on Acute Heart Failure 2022 in Madrid. After reviewing the Phase II trial results, the FDA agreed with the proposed trial design and sample size for the pivotal Phase II trial of dutogliptin in co-administration with filgrastim in early recovery post-myocardial infarction. A comparable agreement was also reached with the EMA.


For further information, refer to the detailed Myocardial Infarction Unmet Needs, Myocardial Infarction Market Drivers, and Myocardial Infarction Market Barriers, click here for Myocardial Infarction Ongoing Clinical Trial Analysis


Myocardial Infarction Emerging Drugs Profile


Empagliflozin: Boehringer Ingelheim

Empagliflozin, is an oral, once-daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk reduction data in its label in several countries. Early use of the SGLT2 inhibitor empagliflozin (Jardiance) after an acute myocardial infarction (MI) improves natriuretic peptide levels and markers of cardiac function and structure.


GNR 060: GENERIUM Pharmaceuticals

GNR 060, is an investigational drug being developed by GENERIUM Pharmaceuticals.GNR 060, belongs to the class of cardiovascular therapies. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Myocardial Infarction.


FDY 5301: Faraday Pharmaceuticals

FDY-5301 is a patented, formulated, elemental reducing agent containing sodium iodide. It works to catalytically destroy hydrogen peroxide, which is naturally generated as a response to acute ischemia-reperfusion injury and contributes to loss of muscle mass and function. Preclinical studies of FDY-5301 have demonstrated its ability to reduce infarct size, improve cardiac function, and improve skeletal muscle function. Phase I data has demonstrated no signs of toxicity in healthy subjects. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Myocardial Infarction.


Zalunfiban: CeleCor Therapeutics

Zalunfiban (RUC-4), a next generation GPI, is specifically designed to be administered subcutaneously to inhibit platelet aggregation for a first-point-of-medical contact treatment to improve outcomes for STEMI patients. Inhibiting platelet aggregation can slow or stop blood clot formation leading to coronary artery blockage, and in turn, can stop or prevent a heart attack.


Zalunfiban targets platelet GPIIb/IIIa receptors, the final common pathway in platelet aggregation, to inhibit all platelet activators and can, under some conditions, promote recanalization of occluded arteries. In contrast, other antiplatelet medications, including P2Y12 inhibitors and aspirin, inhibit only one platelet activator and have not been demonstrated to promote recanalization.


Further, due to decreased gastrointestinal absorption, oral P2Y12 inhibitors given before the procedure to open the artery do not act rapidly or reliably enough in STEMI patients during the crucial early minutes of a heart attack and have not demonstrated a clinical benefit to date. It is currently being investigated in Phase III stage of development for the treatment of myocardial infarction.


Asundexian: Bayer

Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa. By working upstream in the contact activation pathway of coagulation, factor XIa inhibitors may prevent pathologic thrombosis, and thus recurrent ischaemic events, but not adversely impact haemostasis, and thus not cause bleeding.


By specifically targeting a protein involved in pathological thrombus formation, but leaving the pathway involved in physiological vessel healing intact, FXIa inhibitors could have the potential to prevent events like stroke and myocardial infarction (MI) without a corresponding increase in bleeding risk. This program is designed to provide further support for the hypothesis that inhibiting FXIa with asundexian can reduce the risk of thrombotic events without increasing the risk of bleeding. Asundexian is an investigational agent and has not been approved by any health authority for use in any country, for any indication. Asundexian displays potent anticoagulant activity in vitro in human and rabbit plasma and antithrombotic efficacy in vivo in a rabbit arterial thrombosis model.


OPL-0301: Valo Health, Inc.

OPL-0301, which is being developed by Valo Health, acts by targeting sphingosine-1-phosphate (S1P). It is being developed based on the Opal platform. It is administered orally. Valo believes that as a biased S1P1 agonist, OPL-0301 may avoid the side effects of other S1P1 modulators and therefore unlock therapeutic benefit. It is currently being investigated in the Phase II stage of development for the treatment of post-myocardial infarction.

MEDI6570: AstraZeneca

MEDI6570, which AstraZeneca is developing, inhibits the LOX-1 receptor (anti-LOX-1 mAb). Blockade of the receptor reduced cytokine release via the NFkappaB pathway, inhibited monocyte adhesion, prohibited monocyte differentiation to foam cells and smooth muscle cell apoptosis, and improved endothelial function.


MEDI6570 is suitable for post-MI patients with high residual risk attributed to inflammation via direct inhibition of multi-ligand scavenger receptor involved in oxidized LDL pathogenesis and inflammation. It is currently being investigated in the Phase II stage of development for the treatment of coronary heart disease.


Dutogliptin Tartrate: Recardio, Inc.

Dutogliptin Tartrate (REC-01), being developed by Recardio, is a potent and selective inhibitor of Dipeptidyl peptidase 4 (DPP4). Dutogliptin is administered via subcutaneous injection. 

Recardio is currently planning to initiate its global pivotal Phase III clinical program in acute myocardial infarction for market authorization in major markets and will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases.


Myocardial Infarction Pipeline Therapeutics Assessment

There are approx. 60+ key companies which are developing the therapies for Myocardial Infarction. The companies which have their Myocardial Infarction drug candidates in the most advanced stage, i.e. Phase III include, GENERIUM Pharmaceuticals.


Request a sample and discover the recent advances in Myocardial Infarction Ongoing Clinical Trial Analysis and Medications, click here @ Myocardial Infarction Treatment Landscape


Scope of the Myocardial Infarction Pipeline Report


  • Coverage- Global


  • Myocardial Infarction Companies- AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen, Novartis, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, Mesoblast, and others.


  • Myocardial Infarction Pipeline Therapies- FARXIGA/FORXIGA (dapagliflozin), JARDIANCE (empagliflozin), Olpasiran (AMG860), Pelacarsen (TQJ230), Selatogrel, FDY-5301, CSL112, IMT-358, CL2020, MEDI6570, KAND567, Asundexian, Dutogliptin, MPC-25-IC, and others.


  • Myocardial Infarction Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action


Dive deep into rich insights for drugs for Myocardial Infarction Market Drivers and Myocardial Infarction Market Barriers, click here @ Myocardial Infarction Unmet Needs and Analyst Views


Table of Content 

  1. Introduction
  2. Executive Summary
  3. Myocardial Infarction: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Myocardial Infarction – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Empagliflozin: Boehringer Ingelheim
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Asundexian: Bayer
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. SP16: Serpin Pharma
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. TS23: Translational Sciences
  18. Drug profiles in the detailed report…..
  19. Preclinical Stage Products
  20. EndoGuard: EndoProtech Inc.
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Myocardial Infarction  –  Collaborations Assessment- Licensing / Partnering / Funding
  24. Myocardial Infarction  – Unmet Needs
  25. Myocardial Infarction  – Market Drivers and Barriers
  26. Appendix


Got Queries? Find out the related information on Myocardial Infarction Mergers and acquisitions, Myocardial Infarction Licensing Activities @ Myocardial Infarction Emerging Drugs, and Recent Trends


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States